ACY-775 did not cause a significant change in soluble rat tau levels in the AD-tau-treated neurons (Fig. 2D,E), whereas a small increase of soluble tau (p = 0.029) was observed with ACY-1083 (Fig. 2A,B). This evidence concerns the gene MAPT and Alzheimer disease.